The Shkreli Pill

In this episode, Martin examines Micron's recent performance and discusses whether the company's stock has reached a cyclical peak or may be approaching a bottom. He analyzes supply and demand trends in the memory semiconductor market, competitive dynamics, valuation, and the factors he believes could influence Micron's outlook in the coming quarters.

In this episode, Martin discusses potential acquisition targets for Apple and considers how such a move could affect the company's long-term strategy. He also shares his perspective on a possible long position in Oracle, examines developments involving Stripe, and analyzes Celcuity, Electrovaya, and Adicet, discussing each company's business, valuation, and investment outlook.

In this episode, Martin discusses a sharp decline in IBM and considers what it could mean for the broader technology sector. He also provides an analysis of Lumentum (LITE), examining the company's business, competitive position, and outlook, before discussing Adobe's recent stock performance and the factors he believes are contributing to its relative strength.

In this episode, Martin provides an extended analysis of Insmed, examining the company’s commercial products, clinical pipeline, competitive position, and potential growth opportunities. He also discusses the assumptions behind the company’s valuation, the risks surrounding its drug-development programs, and the factors that could shape the stock’s longer-term outlook.

In this episode, Martin discusses recent weakness in IBM and considers whether it could signal broader challenges for other companies in the sector. He also provides a detailed analysis of Bristol Myers Squibb (BMY), examining its business, product portfolio, and valuation, before reviewing Insmed (INSM) and sharing his perspective on the company's prospects and investment outlook.

In this episode, Martin discusses a potential short opportunity involving Bristol Myers Squibb, explaining the factors that have led him to view the company more cautiously. He examines the business, product portfolio, valuation, and competitive landscape, outlining the reasoning behind his investment thesis and the risks he believes investors should consider.

In this episode, Martin discusses a company or market trend that he believes may be approaching a turning point and explains the reasoning behind his outlook. He also examines recent trading activity in Q32 Bio, analyzes Micron’s position in the semiconductor market, and reviews Agenus and Abivax, discussing their pipelines, valuations, and the factors shaping his investment perspective on each co...

In this episode, Martin discusses a market trend that he believes may be nearing its end and explains the reasoning behind that view. He also shares his perspective on SanDisk, outlines his thesis for a short position in Analog Devices, and evaluates Fable, explaining why he has a negative outlook on the company and its prospects.

This compilation brings together Martin’s discussions on how financial markets have evolved and why trading strategies that were successful in the 1990s may be less effective today. Across a range of clips, he examines changes in market structure, technology, quantitative investing, and competition, while sharing his perspective on the skills and approaches he believes are most important for adapt...

In this episode, Martin discusses two short positions that he says have reached their objectives and explains why he is taking profits. He also shares signals generated by his quantitative investment model, highlighting two stocks that it currently identifies as long opportunities and discussing the factors behind those selections and how they fit into his broader investment approach.

In this episode, Martin discusses his view that advances in AI could fundamentally reshape the software-as-a-service (SaaS) industry over the coming years. He explains the reasoning behind this thesis, examines the potential impact of AI agents on software businesses, and shares his perspectives on HubSpot, CAPR, and Nvidia, discussing how these companies may be affected by changing technology tre...

In this episode, Martin challenges a market narrative that he believes investors should view with skepticism before explaining his reasoning. He also analyzes Analog Devices (ADI), discusses his bullish outlook on Google, and shares his views on Oracle and Palantir, examining their valuations, competitive positions, and the factors influencing his investment outlook for each company.

In this episode, Martin shares the long positions currently in his portfolio and explains the investment thesis behind several of his holdings. He also discusses why he believes Samsung has significant upside potential, and comments on a LinkedIn post by the Sellas Life Sciences CEO, examining how it relates to the company and investor sentiment.

In this episode, Martin discusses the market activity surrounding CAPR and shares his perspective on legal action related to the company. He also analyzes Moderna, Adobe, and CRISPR Therapeutics (CRSP), examining their valuations, competitive positions, and future prospects while explaining the factors influencing his outlook on each stock.

In this episode, Martin discusses what he believes Samsung’s recent developments reveal about broader challenges facing the semiconductor industry. He also examines Adobe’s valuation following its recent decline, shares his views on whether the stock has become oversold, and reviews Acadia Pharmaceuticals (ACAD) and Denali Therapeutics, evaluating their businesses, pipelines, and investment outloo...

In this episode, Martin discusses investment opportunities that he believes the broader market may not yet fully appreciate. He shares his views on Nvidia, Apple, and PayPal, examining their valuations, competitive positions, and future prospects. He also offers his perspective on managing portfolio drawdowns, discussing strategies for handling losses, maintaining discipline, and making investment...

In this episode, Martin examines the argument that advances in artificial intelligence could significantly disrupt or replace traditional software companies. He discusses the assumptions behind this view, evaluates which types of businesses may be more or less affected by AI, and shares his perspective on how the technology could reshape the software industry and investment landscape over time.

In this episode, Martin discusses several investment ideas that he believes present attractive opportunities, including Vaxcyte, Vera Therapeutics, and Spruce Biosciences. He also analyzes Tvardi Therapeutics, explaining his perspective on the company's prospects, and outlines his reasoning for taking a short position in OKLO while comparing the risks and potential rewards across these investm...

In this episode, Martin discusses the skills, habits, and mindset he believes are essential for becoming a successful investor. Drawing on his own experience, he shares his perspective on research, decision-making, risk management, and developing an edge in the market, while explaining how investors can improve their analytical process over time.

In this episode, Martin examines whether Meta’s large-scale GPU purchases reflect excessive spending or a strategic advantage based on future AI demand. He also discusses Micron’s outlook in the memory semiconductor market and explores developments related to Elon Musk’s Gigafactory, considering their potential implications for the technology and manufacturing sectors.

In this episode, Martin examines whether the recent performance of AI and memory semiconductor stocks signals a broader shift in the market. He discusses the factors driving the sector, evaluates whether the current cycle may be losing momentum, and shares his perspective on the outlook for AI infrastructure, memory companies, and related investment opportunities.

In this episode, Martin discusses his views on investing in companies associated with Elon Musk and explains why he believes betting against them can be challenging. He also revisits the Theranos case, shares his perspective on concerns surrounding SharonAI, and outlines an approach to rebuilding an investment portfolio following significant gains or losses, with a focus on capital allocation and...

In this episode, Martin examines Meta’s decision to sell AI compute capacity and discusses whether it signals growing overcapacity in the AI infrastructure market. He explores the implications for cloud providers, chipmakers, and AI-related companies, and explains how these developments could affect the next phase of investment in the sector.

In this episode, Martin questions the expectations surrounding SpaceX’s potential valuation by comparing its growth prospects with the broader space industry and government spending. He also turns to the semiconductor sector, discussing recent movement in memory stocks and what changing demand and market conditions could mean for the industry.

In this episode, Martin discusses Meta’s move into the AI cloud business and examines how increased competition could affect existing players in AI infrastructure and computing. He identifies the stocks and companies he believes could face the most pressure, then explores photonic computing and its potential role in the next generation of AI hardware.